INTRODUCTION
Ranibizumab (Lucentis) is a humanised antibody fragment designed to bind and inhibit all vascular endothelial growth factor (VEGF)-A isoforms. 1 It is currently indicated for use in neovascular age-related macular degeneration (NV-AMD) based on the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularisation in AMD (ANCHOR) trial, which showed that monthly intravitreal injections of the drug stabilised visual acuity in 90e95% of patients irrespective of lesion subtype, and improved visual acuity in one in three cases. 2 3 In 2006, the US Food and Drug Administration approved the use of ranibizumab for the treatment of NV-AMD. Following analyses of clinical efficacy and cost-effectiveness of the drug for this condition, the National Institute of Health and Clinical Excellence (NICE) in the UK approved the use of this drug as a loading dose (LD) consisting of three initial injections at monthly intervals followed by OCT (optical coherence tomography)-guided re-treatment. 4 Many patients were initiated on this therapy as soon as the drug was licensed and before the NICE appraisal was completed. These patients received a pro re nata (PRN (as needed)) dosing schedule based on OCT-guided retreatment criteria from the start of the therapy. The objective of this study was to compare the outcomes of the two different protocols: LD versus PRN dosing schedule from baseline.
Methods
This retrospective chart review was conducted at King's College Hospital. The PRN cohort was defined as the cohort before the implementation of the NICE guidance and the LD cohort included consecutive patients soon after the changes of treatment regimen was made to comply with the guidance. All patients were treatment-naive NV-AMD that were initiated on ranibizumab therapy and had completed at least 12 months follow-up. Eyes with subfoveal choroidal neovascularisation (CNV) secondary to AMD of any lesion subtype with lesion size of less than 12 disc areas and visual acuity between 24 and 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Exclusion criteria included patients with CNV secondary to causes other than AMD, lesions previously treated with laser photocoagulation, or intravitreal triamcinolone, intravitreal bevacizumab or photodynamic therapy.
Baseline examination
Each patient underwent best corrected visual acuity measurement with ETDRS charts at 2 m and slitlamp biomicroscopy. Fundus fluorescein angiography was done to assess the lesion characteristics. Baseline qualitative and quantitative assessment of central macular characteristics were measured by OCT (Stratus III OCT; Carl Zeiss, Dublin, California, USA) using six diagonal 6-mm radial line scans and fast macular thickness scans, respectively. Intravitreal ranibizumab (0.5 mg/ 0.05 ml) was given to all patients at baseline.
Re-treatment criteria
Follow-up assessments of visual acuity were done by trained personnel in a busy clinic setting and refraction was not repeated. Biomicroscopy and OCT examinations were done at each monthly visit. Fundus fluorescein angiography was repeated only if an increase in lesions size or new haemorrhage was noted on slit lamp biomicroscopy. Patients on LD regimen received two further consecutive monthly intravitreal ranibizumab injections independent of clinical findings. Further injections were determined by the same re-treatment criteria as patients on PRN schedule from baseline.
Criteria for retreatment included: (1) recurrence of any subretinal fluid (SRF) or intraretinal fluid (IRF) on OCT in a previously dry macula; (2) persistent SRF and/or IRF; (3) decrease of five letters (ETDRS) associated with fluid on OCT; (4) new haemorrhage and/or angiographic evidence of increase in lesion size.
The presence of pigment epithelial detachments (PED) was not considered as a re-treatment criterion.
Outcome measures
Main outcome variables in the two treatment groups were visual acuity and central macular thickness (CMT) at different time points. One month was defined as an interval of 30610 days. The last observation carried forward method was applied to replace missing values to the last measurement. The influence of baseline lesion characteristics on final visual outcome was analysed using a linear regression model. Statistical significance was set at p<0.05 for all analyses.
RESULTS

Patient demographics
Seventy-eight eyes of 78 consecutive patients that met the inclusion criteria were included in this study. There were more women (n¼50) than men (n¼28). The average age of patients was 80.67 (range 67e91) years. The mean duration of symptoms was 3.28 months (range 1 weeke12 months). The average time interval from point of first diagnosis (optician or general ophthalmologist) to treatment was 5.3 (range 0e24) weeks. The main reasons for the delay to initiate treatment were delay in referral from one hospital to another and approval of funding of the drug before the NICE guidelines in 2008. The baseline characteristics of the two groups are shown in table 1.
Visual outcome
Baseline mean visual acuity at baseline was 48615.25 ETDRS letters in the LD group and 44.48615.41 ETDRS letters in the PRN group. The proportions of patients that gained vision ($15 letters) was 29.8% in the LD group compared with 12.9% in the PRN group (p¼0.01). There were no statistical differences in the proportions that stabilised vision (loss of less than 15 letters) or lost vision (loss of 15 or more letters) in the two groups at 12 months (table 2) . There were also no significant differences in mean change in visual acuity at any time point during the 12 months (figure 1). At the end of 12 months, the LD group gained a mean of 4.44 letters from while the PRN group gained 4.03 letters. The maximum mean gain in visual acuity was noted at the end of 3 months in LD of +7.7 letters while the PRN group reached a maximum of + 6.2 letters at 6 months.
Central macular thickness
There were no significant differences in CMT at any time point (table 3) . The influence of baseline lesion characteristics (SRF, IRF, PED, macular volume) on the initial visual acuity and final visual acuity post-treatment was analysed using a stepwise linear regression model with SRF, IRF and PED handled as categorical variables (table 4) . None of the baseline characteristics were found to have any influence on outcome post treatment between the two groups.
Treatment frequency
The mean number of ranibizumab injections was 4.5 in the PRN group and 6.0 in the LD group. Overall, 422 injections were performed for this cohort during the 12-month period, with a mean number of injections of 5.41. The distribution of injections every 3 months in the two groups is shown in table 5. The mean numbers of injections received by the two groups at different time points are shown in figure 2 . At the time of last follow-up, 15/47 (31.91%) eyes in LD group and 11/31 (35.48%) in the PRN group were still active as defined by the criteria for re-treatment stated above.
Subgroup analyses
The patients in the PRN group were classified into those that required less than or equal to three injections or more than three to assess predictive factors that could determine lesions that require less number of injections (table 6 ). There were no significant differences in baseline features that could predict the need for less number of injections. In the PRN group: 9.68% patients received only one injection, 64.52% received two injections and 25.80% received three injections in the first 3 months. Re-analysis of the visual outcome after excluding the patients who received three injections in the PRN cohort did not reveal a significant difference. In the LD group, only 12.77% of the eyes received a total of three injections only.
Complications
Complication included retinal pigment epithelial tear in seven eyes (four in LD group and three in PRN group) and one eye in the PRN group developed acute anterior uveitis that was successfully treated with a course of topical steroids and cycloplegic drops. All the eyes with retinal pigment epithelial tear had pigment epithelial detachment at baseline presentation. There were no cases of endophthalmitis or retinal detachment.
DISCUSSION
We compared two treatment regiments with ranibizumab for NV-AMD. The LD received a loading dose of three ranibizumab injections followed by an as-needed dosing schedule. The PRN group received ranibizumab injections as-needed from baseline. The re-treatment criteria for the as-needed part of the arms were derived from the Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab (PrONTO) study that showed that an OCT-guided regiment resulted in a mean gain of +9.3 letters with a mean injection frequency of 5.6. 5 Our study showed that the mean gain in vision in the whole cohort was +4.2 letters with a mean injection frequency of 5.41 injections in 12 months. Although the dosing schedules were different in the two groups, the overall re-treatment criteria after 3 months were similar in the two groups. We also believe that we had a lower threshold to treat compared with the PrONTO study at 12 months because we did not consider any minimum numerical changes in CMT and treatment was initiated if any fluid was present on OCT. Despite that, the overall result of the cohort showed that the mean gain in visual acuity was only approximately half that obtained in the PrONTO study.
Caution should be expressed when we compare our cohort with the PrONTO study because the PrONTO cohort were not treatment-naive. In fact, the study better reflects the visual gain achieved by the Study of Ranibuzumab in Patients with Subfoveal Choroidal Neovascularization Secondary to AgeRelated Macular Degeneration (SUSTAIN) study of +3.6 letters at 12 months with a mean injection rate of 5.7 at 12 months. The SUSTAIN study evaluated the outcome of three loading doses of ranibizumab followed by as-needed OCT-guided dosing regimen on 531 patients with NV-AMD. Similarly, our results also mirror the outcomes of the lucentis monotherapy arm of the Verteporfin Photodynamic Therapy Administered in Conjunction with Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation Secondary to AMD (MONT BLANC) study that showed a mean gain of 4.4 letters with a mean injection rate of 5.1 at end of 12 months. Our study mirrors the results of the SUSTAIN and MONT BLANC studies and demonstrates that a PRN dosing schedule with a mean of five injections annually will only result in a gain of approximately one ETDRS line of vision in real-life settings.
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This study also showed that nearly three times as many patients in the LD group gained vision compared with the PRN group at 12 months. In fact, on further analyses of frequency of injections, the time point of maximum gain of vision in both groups correlates with greatest frequency of injections given.
The LD had the maximum mean gain in vision of +7.7 letters at 3 months and these results do not differ significantly from the results obtained in the SUSTAIN study of +5.8 respectively. The PRN group had their maximum visual gain at 6 months (+6.8 letters) and this correlates to the maximum number of injections given to the PRN group in this period. However, the maximum gain in the PRN group is less than the LD group suggesting that three loading doses are required to achieve maximum potential gain of vision.
The visual outcomes at different time points were not dependent on any baseline features of the subfoveal lesion or OCT characteristics. Although the sample size was small for subgroup analyses of the PRN group, there were no obvious predictive factors that determined the groups of patients that required less than three injections based on the re-treatment criteria used in this study.
Subgroup analyses of the ANCHOR and MARINA studies indicated that the baseline visual acuity, lesion size and age were the important predictors of final visual outcome. This study did not show any of these factors to be relevant, probably due to the smaller sample size, but more importantly, it could be due to the fact that the injection frequency may be the most important predictor of final visual outcome. Our study substantiates the study by Dadgostar et al 8 that indicated that visual improvement after ranibizumab is related to the frequency of injections received and not to the resolution of fluid by OCT. Michalova et al 9 demonstrated results similar to those of the MARINA and ANCHOR study on 185 patients with a mean injection rate of nine injections in 12 months. Although the baseline mean visual acuity was better (57.6 615.5 ETDRS letters) in that study compared with the present study, the higher rate of injections may also explain the difference in visual outcome between the studies.
There are two published studies that used a PRN dosing schedule from baseline. Both Rothenbuehler et al 10 and Querques et al 11 reported visual acuity comparable to those found in the MARINA, ANCHOR and PrONTO studies. Despite the same treatment protocol, the mean number of injections in the study of Rothenbuehler et al was 5.662.9 at 12 months and that of Querques et al was 5.1062.5, but our PRN group required a mean of only 4.562.0 injections. The limitations of our study are the retrospective nature and the lack of standardised visual acuity measurements. However, the mean change in visual acuity in the other eye was À1.5 ETDRS letters, suggesting that the report is an accurate estimate of changes in visual acuity. Recent publications of several studies of real-life outcomes of OCT-guided ranibizumab therapy show significant differences in outcomes, indicating that re-treatment based on changes in visual acuity and OCT may not be sufficient to obtain optimal results. A recent study showed that other tests of visual function such as microperimetry may be a superior tool compared with visual acuity. 12 Similarly, this study was based on Stratus OCT (Carl Zeiss) and now with the availability of new spectral domain OCT, patients in the same clinic settings require more injections, suggesting that we may have under-treated patients previously using time domain OCT.
Despite the significant increase in the number of hospital visits for patients, increased work-load for retinal specialists and consequent increase in economic burden to healthcare providers, this study and the review of published studies show that improvement in visual acuity is best achieved with a loading dose of three injections and higher rate of injections. These findings should be validated in further randomised clinical trials. 
